Fig 4.

Effect of IL-2 CLDC treatment on clinical signs in adult client-owned cats with chronic rhinitis. Client-owned adult cats (group 3) were randomized to 4 weeks of treatment with intraperitoneal injection once weekly with 150 μg IL-2 CLDC (Treatment, n=5), or were randomized to treatment with liposomes only (Placebo, n=7). The mean (+SD) of the owners' evaluations of changes in clinical scores at each week, compared to baseline values, were tabulated and plotted. Compared to pre-treatment signs, cats randomized to the IL-2 CLDC treatment group had a significant improvement in sneezing (P=0.016) but not in the frequency of nasal discharge (P=0.063).